IN Brief:
- HTBA’s first acquisition adds Specnova’s LipoVantage and NovaQSpheres technologies.
- LipoVantage uses powdered liposomal encapsulation, while NovaQSpheres uses multilayer beadlets for controlled release.
- HTBA and Specnova will continue operating independently while collaborating on new ingredient applications.
HealthTech Bio Actives has acquired US biotechnology company Specnova, adding liposomal encapsulation and controlled release technologies to its existing portfolio of bioactive ingredients.
The transaction is HTBA’s first acquisition. The two businesses will continue operating independently while collaborating on ingredient development for supplements, food and beverage applications, combining HTBA’s manufacturing base with delivery systems developed by Specnova.
HTBA already produces bioactive ingredients including citrus flavonoids and active forms of vitamin B12. Specnova works on the structure surrounding an active ingredient, using encapsulation or multilayer systems to alter how the material is protected, dispersed and released.
LipoVantage uses liposomes formed from phospholipid bilayers to surround active material. Specnova produces the system as a free flowing, water soluble powder, allowing the encapsulated ingredient to be handled through conventional dry blending and dosing operations rather than requiring a liquid liposomal preparation.
That powder format opens several production routes, including tablets, capsules, gummies, powders, functional foods and beverages. Each application still places different demands on the encapsulated material because mixing, hydration, heat, acidity and storage can affect the integrity of the delivery structure before the product is consumed.
Specnova adds another protective layer through its DualHydrogel system, which surrounds the liposomal structure with a hydrogel matrix. The company uses the design to improve physical stability during manufacture and storage while protecting the encapsulated material until use.
NovaQSpheres approaches delivery differently. Active ingredients are incorporated into multilayer beadlets surrounded by a membrane containing polymers and cyclodextrins, allowing the structure to release material progressively rather than making the full dose available immediately.
The release profile can be adjusted according to the ingredient and intended application, giving formulators another variable beyond concentration alone. A controlled release ingredient therefore has to be selected around the required behaviour after consumption as well as its performance during manufacturing.
Both technologies introduce additional processing constraints. Liposomal powders have to disperse without destroying the structures intended to carry the active ingredient, while beadlets must survive blending, compression or other manufacturing stages without breaking before the finished product reaches the consumer.
Particle size can also affect food and beverage applications directly. A delivery system that performs successfully inside a capsule may create visible sediment, grittiness or opacity when dispersed in a drink, while inclusion in a bar or chew exposes the particles to different mechanical forces and moisture conditions.
HTBA’s applications capability gives the combined businesses a route to address those problems alongside ingredient production. Development work can incorporate the active compound and delivery technology together, allowing stability, dosage, processing conditions and sensory effects to be assessed as part of one formulation rather than as separate components.
The acquisition also expands HTBA’s position in the United States, where Specnova is based. Retaining separate operating structures should allow Specnova to continue its existing technology development while HTBA adds manufacturing, customer access and formulation resources where the companies’ portfolios overlap.
Functional foods and beverages are creating more demanding development briefs as manufacturers combine proteins, minerals, botanicals and other active ingredients inside formats originally designed around taste and convenience. Many of those compounds are difficult to disperse, unstable during processing or unpleasant at concentrations required to support the intended formulation.
Encapsulation can protect sensitive material or mask part of its interaction with the surrounding food matrix, although the added structure brings cost, processing and regulatory considerations of its own. The useful comparison is therefore not whether a delivery platform is technically more complex, but whether that complexity solves a problem that would otherwise prevent the ingredient being used effectively.
Controlled release introduces another design choice because immediate availability is not always the intended outcome. Beadlet architecture can determine where and how quickly an active ingredient is released, but the finished format must preserve that architecture through storage and manufacture before it reaches the digestive conditions for which it was designed.
HTBA can now develop those delivery considerations alongside its own bioactive ingredients rather than treating them as technologies supplied by separate businesses. The commercial value will depend on formulations that retain the intended release or protection mechanism after industrial processing and still meet the taste, texture and shelf life requirements of the final product.
